Efficacy of HCV core antigen detection during the preseroconversion period

Couroucé, Anne‐Marie; Marrec, N. Le; Bouchardeau, Françoise; Razer, Annie; Maniez, M.; Laperche, Syria; Simon, Nicole

doi:10.1046/j.1537-2995.2000.40101198.x

Cited by 94 publications

(103 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first was developed by Tanaka et al (28) in 1995, and then Aoyagi et al (2) developed a new and 100-fold more sensitive test in 1999. In previously reported studies, HCV Ag was detected 1 day later than HCV RNA in patients undergoing seroconversion (5,6,20).…”

Section: Discussionmentioning

confidence: 76%

“…The anti-HCV test does not distinguish the individuals who have resolved HCV infection from the patients with active/ongoing HCV infection. As a consequence, anti-HCV assay results with values under the critical value used by EIA or CLIA need to be confirmed by an additional confirmatory test, such as the HCV RNA test, or with the preconfirmatory HCV Ag assay (5,10,14,17,25).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of a Newly Developed Automated and Quantitative Hepatitis C Virus (HCV) Core Antigen Test with the HCV RNA Assay for Clinical Usefulness in Confirming Anti-HCV Results

et al. 2011

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a global health care problem. Diagnosis of HCV infection is mainly based on the detection of anti-HCV antibodies as a screening test with serum samples. Recombinant immunoblot assays are used as supplemental tests and for the final detection and quantification of HCV RNA in confirmatory tests. In this study, we aimed to compare the HCV core antigen test with the HCV RNA assay for confirming anti-HCV results to determine whether the HCV core antigen test may be used as an alternative confirmatory test to the HCV RNA test and to assess the diagnostic values of the total HCV core antigen test by determining the diagnostic specificity and sensitivity rates compared with the HCV RNA test. Sera from a total of 212 treatment-naive patients were analyzed for anti-HCV and HCV core antigen both with the Abbott Architect test and with the molecular HCV RNA assay consisting of a reverse transcription-PCR method as a confirmatory test. The diagnostic sensitivity, specificity, and positive and negative predictive values of the HCV core antigen assay compared to the HCV RNA test were 96.3%, 100%, 100%, and 89.7%, respectively. The levels of HCV core antigen showed a good correlation with those from the HCV RNA quantification (r ‫؍‬ 0.907). In conclusion, the Architect HCV antigen assay is highly specific, sensitive, reliable, easy to perform, reproducible, cost-effective, and applicable as a screening, supplemental, and preconfirmatory test for anti-HCV assays used in laboratory procedures for the diagnosis of hepatitis C virus infection.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Comparison of a Newly Developed Automated and Quantitative Hepatitis C Virus (HCV) Core Antigen Test with the HCV RNA Assay for Clinical Usefulness in Confirming Anti-HCV Results

et al. 2011

View full text Add to dashboard Cite

show abstract

“…24 Courouse et al studied 135 serial specimens from 28 haemodialysis patients, and found that 88% of viraemic specimens contain HCVcAg. 26 One of our Devesa et al observed restricted antibody reactivity to Hepatitis C Virus synthetic antigens in patients on haemodialysis. 27 In the RIBA strip NS3 and NS5 antigen bands are recombinant proteins and the core and NS4 bands are of synthetic antigens.This could be one of the reasons for greater antibody response towards NS3 antigen among our haemodialysis patients.…”

Section: Discussionmentioning

confidence: 88%

Prevalence of HCV Infection in Patients on Haemodialysis: Survey by Antibody and Core Antigen Detection

Reddy¹,

Murthy²,

Lakshmi³

2005

Indian J Med Microbiol

View full text Add to dashboard Cite

Purpose: The present study was undertaken to determine the prevalence of HCV infection by antibody testing and HCV core antigen (HCVcAg) determination by ELISA in haemodialysis patients and to evaluate the HCV c Ag assay in the detection of HCV infected patients on haemodialysis. Materials and Methods: A total of 151 chronic renal failure patients on haemodialysis from May 2003 to October 2004 were studied. One hundred patients out of 151 were followed for 2-5 months. All the patients were tested for anti HCV and HCV core antigen once a month. Anti HCV ELISA positive specimens were confirmed by RIBA. Results: The overall prevalence of HCV infection was 13.23%. Antibody positivity was observed in 9.93% and HCVcAg alone was detected in 2.64%. One patient (0.66%) was initially positive for core antigen and later seroconverted. Conclusions: Screening for HCV antibodies alone does not exclude infection with HCV in patients on haemodialysis and HCVcAg may be a useful test for identifying HCV infected patients on haemodialysis in the early phase of infection before seroconversion.

show abstract

“…False negative anti-HCV EIA results may occur in HIV-infected persons with advanced immune suppression (CD4 < 100/mm 3 ) and true negative EIA are common in the setting of acute HCV infection ( < 12 weeks following acquisition) prior to seroconversion [20][21]. If serologic test results are negative and HCV infection is suspected due to elevated liver enzyme levels or risk factors such as intravenous drug usage or high-risk sex, HCV RNA testing should be performed.…”

Section: Discussionmentioning

confidence: 99%

Detection of Hepatitis C virus and Human immunodeficiency virus in expatriates in Saudi Arabia by antigen-antibody combination assays

Alzahrani

Obeid

Al-Ali

et al. 2009

J Infect Dev Ctries

View full text Add to dashboard Cite

Background: The simultaneous detection of antigen and antibody was originally described for the early detection of the human immunodeficiency virus (HIV). The same approach was applied to detect the hepatitis C virus (HCV). The aim of this work was to use the antigen and antibody combination assay for the detection of HCV and HIV infections in expatriates in Eastern Saudi Arabia. Methodology: The study group (N = 875) included expatriate workers of both sexes who were undergoing mandatory pre-employment testing. Detection of anti-HCV antibodies, HCV core antigen, HCV viral RNA, HIV antigens and antibodies was conducted using commercially available kits. Results: Of the 875 samples that were screened for HCV-specific antibodies, four (0.46%) tested positive (two from Pakistan, one from India, and one from the Philippines) and two (0.23%) were equivocal (one from Egypt and one from Nepal). All four samples that were positive for HCV-specific antibodies also tested positive using HCV RNA assay and the HCV antigen-antibody combination assay. The two samples that were equivocal tested positive using the HCV RNA assay and the HCV antigen-antibody combination assay. Of the 875 samples that were tested for HIV antibodies, only one (0.11%) sample gave repeatedly positive results. The same sample also tested repeatedly positive using the HIV combination assay. These results were subsequently confirmed by HIV western blot assay. Conclusions: Our study indicates that the addition of antigen detection to the screening of HCV and HIV may lower the risk of transmission of these viruses in the host country and contribute to the overall control of HCV and HIV in Saudi Arabia.

show abstract

Efficacy of HCV core antigen detection during the preseroconversion period

Abstract: HCV Ag testing permits the detection of an HCV infection about 1.5 months earlier than the HCV Ab screening tests and an average of only 2 days later than quantitative HCV RNA detection in individual specimens.

Cited by 94 publications

References 14 publications

Comparison of a Newly Developed Automated and Quantitative Hepatitis C Virus (HCV) Core Antigen Test with the HCV RNA Assay for Clinical Usefulness in Confirming Anti-HCV Results

Comparison of a Newly Developed Automated and Quantitative Hepatitis C Virus (HCV) Core Antigen Test with the HCV RNA Assay for Clinical Usefulness in Confirming Anti-HCV Results

Prevalence of HCV Infection in Patients on Haemodialysis: Survey by Antibody and Core Antigen Detection

Detection of Hepatitis C virus and Human immunodeficiency virus in expatriates in Saudi Arabia by antigen-antibody combination assays

Contact Info

Product

Resources

About